New   AI-assisted compliance for Indian businesses. Plan your India entry → ☎ +91-8586441494 contact@kamrit.com Login →

Business Plans › Healthcare

Eye Care / Optical Store Business Plan & Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Report Format: PDF + Excel  |  Report ID: KMR-SVB-033  |  Pages: 183

Market size, FY2026

₹14,200 crore

CAGR 2025-2032

13.5%

CapEx range

₹10 lakh - ₹40 lakh

Payback

2 - 3 yrs

Kochi location overlay for this report

Setting up eye care / optical store & in Kochi, Kerala

Pharma units require Schedule M layout (10000-30000 sqft for small-MSME), HVAC, water-for-injection facility, and drug-controller-licenced storage. At a CapEx of ₹10 lakh - ₹40 lakh, this project lands inside the bands the Kerala industrial-policy team treats as MSME / mid-cap. Power, land, and effluent-disposal costs in Kochi determine the OpEx profile shown below.

Kochi industrial land cost

₹38k-₹95k / sq m (Kakkanad, Cherthala, Kinfra industrial parks)

Kochi industrial tariff

₹7.4-8.8 / kWh

Nearest export port

Cochin Port (in-city) + ICTT Vallarpadam

Kerala industrial policy

Kerala Industrial Policy 2023: capital subsidy up to 35%, interest subsidy 5%, special incentives for non-Annexure-3 sectors

Eye Care / Optical Store &: DPR Summary

₹14,200 crore of addressable demand today, ₹34,456 crore by 2032 by the end of the forecast period, and 13.5% CAGR. That is the headline frame for the Indian eye care / optical store category. KAMRIT's DPR is positioned for a sub-₹25-lakh micro-enterprise project at ₹10 lakh - ₹40 lakh CapEx with 2 - 3-year payback, anchored on screen time vision strain and brand penetration and benchmarked against Lenskart, Titan Eyeplus, Vision Express.

CapEx ₹10 lakh - ₹40 lakh for a sub-₹25-lakh micro-enterprise setup in the Indian eye care / optical store sector, with a 2 - 3-year payback against a ₹14,200 crore → ₹34,456 crore by 2032 market (13.5%). Screen time vision strain is the structural tailwind.

The report is positioned for a micro entrant and is structured for direct submission to a commercial bank or NBFC for term-loan sanction under the Means of Finance set out below.

Regulatory and licence map for this eye care / optical store project

Eye care / optical store sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹10 lakh - ₹40 lakh CapEx this DPR captures:

  • Bio-medical waste authorisation under BMW Rules 2016
  • PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
  • NABH / NABL accreditation if the project includes a clinical or diagnostic arm
  • Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
  • CDSCO + State Drug Controller dual approval for new formulations

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

Sectoral context for this eye care / optical store & project

India supplies 50 percent of the world's vaccine demand and 40 percent of US generics. Within that base, the eye care / optical store category is at ₹14,200 crore and growing 13.5%. Three forces favour new entrants here: screen time vision strain, brand penetration, and Ayushman Bharat-driven insurance penetration that adds ₹85,000 crore of new addressable demand. Lenskart sets the competitive benchmark in margin and channel reach.

Project-specific demand drivers

  • Screen time vision strain
  • Brand penetration
  • Sunglasses fashion
  • Premium lens demand

Technology and machinery benchmarks

For eye care / optical store, the technology selection within KAMRIT's Tier 2 Bankable DPR is comparison-led across Indian, Chinese, European, and Japanese suppliers. Capex per unit of output, energy consumption, manpower per shift, output quality, and after-sales support availability inside India are scored together to pick the path that balances entry capex against operating cost. At this scale, Indian-made or refurbished imported equipment typically delivers 30-45% capex compression versus brand-new European/Japanese options without material productivity loss.

Bankable Means of Finance for this eye care / optical store project

For a eye care / optical store project at ₹10 lakh - ₹40 lakh CapEx with a 2 - 3-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 20-30% promoter equity and 70-80% debt. The primary lender pool for this scale is MUDRA Tarun (up to ₹10 lakh), PMEGP (15-35% subsidy on up to ₹25 lakh). The applicable overlay schemes that materially compress effective cost-of-capital are Stand-Up India ₹10 lakh-₹1 cr for SC/ST/women, CGTMSE collateral-free up to ₹2 cr. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

Risks and mitigation for this project

For eye care / optical store at ₹10 lakh - ₹40 lakh CapEx and 2 - 3-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For this category specifically, KAMRIT also models supplier concentration risk, currency exposure where input-imports exceed 25 percent of CapEx, and the working-capital cycle stretch in the first 18 months of commissioning. The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.

How to engage with KAMRIT on this report

KAMRIT offers three engagement tiers tailored to the decision stage of the project. Pick the tier that matches what you actually need: pricing, scope, and turnaround are summarised in the sidebar.

Key market drivers

  • Screen time vision strain
  • Brand penetration
  • Sunglasses fashion
  • Premium lens demand

Competitive landscape

The Indian eye care / optical store market is sized at ₹14,200 crore in 2026 and is on a 13.5% trajectory to ₹34,456 crore by 2032. Lenskart, Titan Eyeplus and Vision Express hold the leading positions , with Lawrence & Mayo, Specsmakers, Cohens Fashion Optical also profiled in this DPR. The full report benchmarks the new entrant's CapEx (₹10 lakh - ₹40 lakh) and unit economics against the listed-peer cost structure, identifies the specific competitive gap a 2 - 3-year-payback project can exploit, and includes channel-share and pricing-position analysis. Click any name to open its live profile, current stock price, and analyst note.

Lenskart Titan Eyeplus Vision Express Lawrence & Mayo Specsmakers Cohens Fashion Optical

What's inside the Eye Care / Optical Store DPR

The Eye Care / Optical Store DPR is a 183-page PDF (Tier 2 also ships an Excel financial model) built around a micro entrant assumption. It covers Schedule M-compliant layout, GMP cleanroom mapping, HVAC and WFI water system sizing, QA / QC lab design, validation protocols, and dossier preparation for CDSCO and export markets. The financial side runs the full project economics for ₹10 lakh - ₹40 lakh CapEx: line-itemised CapEx with vendor quotes, OpEx build-up by cost head, 5-year revenue projection by SKU and channel, P&L / balance sheet / cash flow, ROI, NPV, IRR, working-capital cycle, break-even, three-scenario sensitivity, and the Means of Finance recommendation. Payback of 2 - 3 years is back-tested against the listed-peer cost structure of Lenskart and Titan Eyeplus.

Numbers for this Eye Care / Optical Store & project

Market, operating, and project economics at a glance

A focused view of the numbers that decide this micro project. The Bankable DPR breaks each of these down into the full state-by-state and vendor-by-vendor schedule.

Indian market

₹14,200 crore

as of FY26

Forecast

₹34,456 crore by 2032

13.5% CAGR

Project CapEx

₹10 lakh - ₹40 lakh

micro entrant

Payback

2 - 3 yrs

base-case scenario

GMP CapEx

₹8-14 cr / line

tablet line, Grade C

Validation cost

₹40-80 lakh

WHO-GMP audit ready

DPCO exposure

~14%

NLEM essential category

GST rate

5-12%

formulations vs APIs

City-specific versions of this report

Setting up in your city? 20 location-specific overlays included.

Each city version of this report layers in state-specific subsidies, the local industrial land cost band, electricity tariff, distance to the nearest export port, and the closest state industrial policy headline: useful when shortlisting a location for your unit.

Table of Contents

20 chapters, 183 pages. Excel financial model included with Tier 2 and Tier 3.

Executive Summary 5 pages
Industry Overview & Market Size 12 pages
Demand Analysis & Customer Segmentation 10 pages
Regulatory Framework, Licences & Registrations 14 pages
Location & Footfall Strategy (Tier-1, Tier-2 city overlay) 12 pages
Service Design & SOP / Operating Manual 12 pages
Equipment, Fit-out & Interior CapEx Schedule 10 pages
Technology Stack (POS, CRM, booking, payments) 8 pages
Manpower Plan, Training & Retention 8 pages
Branding, Customer Acquisition & Marketing Plan 12 pages
Project Cost (CapEx) & Means of Finance 10 pages
Operating Cost (OpEx) Build-Up 10 pages
Revenue Projections (3-year, by service/SKU) 8 pages
Profitability, ROI & Per-Outlet Unit Economics 10 pages
Break-Even & Sensitivity Analysis 8 pages
Working Capital & Cash Cycle 6 pages
Franchise / Multi-Outlet Expansion Plan 8 pages
Risk Assessment & Mitigation 6 pages
Competitive Landscape & Key Players 10 pages
Conclusion & Recommendations 5 pages

FAQs about this Eye Care / Optical Store & project

Does this eye care / optical store project need Schedule M cleanrooms?

For formulations: yes, Schedule M (revised) is mandatory from 2024. Grade D / C / B classification depends on dosage form. KAMRIT sizes the HVAC, WFI water system, and cleanroom CapEx accordingly within the ₹10 lakh - ₹40 lakh envelope.

WHO-GMP and US-FDA , which export markets does this DPR target?

KAMRIT structures the dossier for WHO-GMP (regulated emerging markets) by default. US-FDA (ANDA filing) and EU-GMP add 18-24 months to the timeline and 35-50% to validation CapEx. The Tier 2 DPR runs both scenarios.

Is the project under DPCO / NLEM price control?

Essential medicines on the NLEM are price-controlled by NPPA. KAMRIT confirms upfront whether the product portfolio is exposed, since DPCO controls compress gross margin by 8-14 percentage points.

What CDSCO approvals apply?

For new formulations, dual approval from CDSCO and the State Drug Controller. Form 25/28/28A depending on category. Bioequivalence studies for generics. KAMRIT handles the dossier preparation, regulator interaction, and audit readiness.

What is the typical payback for eye care / optical store?

For ₹10 lakh - ₹40 lakh CapEx, KAMRIT's base case lands payback at 2 - 3 years assuming 70% capacity utilisation by Year 3. Export-led units (with 30%+ revenue from US/EU) hit payback 12-18 months faster.

How quickly can KAMRIT start on this project?

KAMRIT begins the file within one business day of the engagement letter. Tier 1 Industry Insights Report ships in 7 business days, Tier 2 Bankable DPR with Excel model in 14 business days, and Tier 3 Execution Partnership is custom-scoped 6-18 months depending on the project envelope.

Not sure which tier you need?

Senior Partner Vishal Ranjan or Associate Vidushi Kothari will take a 20-minute scoping call and recommend the right engagement tier for your decision stage. Response within one business day.